Senneville Eric, Gachet Benoit, Blondiaux Nicolas, Robineau Olivier
Infectious Diseases Unit, Gustave Dron Hospital, F-59200 Tourcoing, France.
French National Referent Centre for Complex Bone and Joint Infections, CRIOAC Lille-Tourcoing, F-59000 Lille, France.
Antibiotics (Basel). 2023 Feb 3;12(2):317. doi: 10.3390/antibiotics12020317.
The choice of antibiotic regimens for use in patients presenting with diabetic foot osteomyelitis and their duration differs according to the situation. Antibiotics play a more important role in the medical option where no infected bone has been resected, while their role is reduced but not negligible in the case of surgical options. Some studies have reported the presence of biofilm structures in bone samples taken from patients with diabetic foot osteomyelitis, which raises the question of the place of anti-biofilm antibiotic regimens in this setting. During the last two decades, clinical studies have suggested a potential benefit for anti-biofilm antibiotics, mainly rifampicin against staphylococci and fluoroquinolones against gram-negative bacilli. However, no data from randomized controlled studies have been reported so far. The present work provides a summary of the available data on the question of the place of anti-biofilm antibiotics for the treatment of diabetic foot osteomyelitis, but also the potential limitations of such treatments.
对于患有糖尿病足骨髓炎的患者,抗生素治疗方案的选择及其疗程会因情况而异。在未切除感染骨的药物治疗方案中,抗生素发挥着更重要的作用,而在手术治疗方案中,其作用虽有所降低但并非微不足道。一些研究报告称,从糖尿病足骨髓炎患者采集的骨样本中存在生物膜结构,这就引发了在这种情况下抗生物膜抗生素治疗方案的地位问题。在过去二十年中,临床研究表明抗生物膜抗生素可能有益,主要是利福平针对葡萄球菌,氟喹诺酮类针对革兰氏阴性杆菌。然而,迄今为止尚未有随机对照研究的数据报道。本研究总结了关于抗生物膜抗生素在糖尿病足骨髓炎治疗中地位问题的现有数据,以及此类治疗的潜在局限性。